BlackRock Health Sciences Opportunities Portfolio Investor A Shares
SHSAX
NASDAQ- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 100 Bellevue Parkway Wilmington DE United States of America 19809
- IPO Date
- Dec 20, 1999
- CIK
- 0000844779
- Website
- blackrock.com
- Similar Companies
- Business
- BlackRock Health Sciences Opportunities Portfolio Investor A Shares (SHSAX) is an open-end mutual fund that seeks long-term growth of capital by investing at least 80% of its total assets in equity securities, primarily common stocks, of companies in health sciences and related industries; these include health care equipment and supplies, health care providers and services, biotechnology, pharmaceuticals, and other relevant sectors. The fund concentrates more than 25% of its assets in health sciences industries and may invest in non-U.S. companies, with a portfolio that as of late 2025 features top holdings such as Eli Lilly and Company (10.88%), Johnson & Johnson (8.36%), Abbott Laboratories (5.02%), AbbVie Inc. (3.96%), and Thermo Fisher Scientific Inc. (3.69%), alongside approximately 153 total holdings predominantly in U.S. stocks (94.87% allocation) and minor exposure to non-U.S. stocks (4.14%). It operates within the Morningstar Health category, targeting investors seeking exposure to large-cap value stocks in the healthcare sector, with assets under management exceeding $6.3 billion and a net expense ratio of 1.09%. Launched on December 21, 1999, and domiciled in the United States with management by BlackRock at its headquarters in New York, NY, the fund is available to U.S. investors through channels like Schwab with a minimum initial investment of $1,000. Portfolio management is led by Erin Xie since July 31, 2003, and Xiang Liu since June 1, 2020. The fund maintains a portfolio turnover of 43% and does not pursue an ESG, sustainable, or impact investment strategy. In recent developments, the fund has sustained its core strategy amid market volatility, with year-to-date returns reflecting resilience in healthcare equities as of December 2025; no major acquisitions, partnerships, funding rounds, or structural reorganizations specific to SHSAX have been reported in the last 1-2 years, though BlackRock as the parent continues broader institutional expansions in asset management. Performance metrics show annualized returns of 7.79% over three years and 9.20% over ten years (total return basis), positioning it competitively in its Lipper and Morningstar quartiles.